The disclosure relates to a pharmaceutical composition formulated for transmucosal delivery in the salivary mucosal environment particularly for sublingual or buccal delivery, wherein the composition includes at least one tocotrienol or derivative thereof together with one or more pharmaceutically acceptable excipients. The present disclosure further relates to the use of said compositions for treating or preventing post exercise muscle soreness, delayed onset muscle soreness, cardiac fibrosis, hypertension, inflammation, stroke, cancer, elevated cholesterol and/or triglycerides, baldness, hypertrophy, conditions resulting from radiation exposure, stabilizing and/or controlling blood glucose levels, and improving exercise endurance and capacity.
